3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Melanoma
5
Breast Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Thyroid Neoplasms
1
Ovarian Cancer Metastatic
1
Neoplasms
1
Multiple Myeloma
1
Metastatic HPV-16 Positive Squamous Cell Anal Cancer
1
Metastatic Bladder Urothelial Carcinoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Adenocarcinoma of Lung
1
Interventions
fludarabine
1
aldesleukin
1
Interleukin-2
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Ovarian Cancer Metastatic
×
aldesleukin
×
Clear all
NCT04389229
2020-12-16
OVSTAR
Immetacyte Ltd
Phase 1/2
Withdrawn